Global pharmaceutical giant Lupin Limited has secured approval from China for Oseltamivir Phosphate, marking a major milestone in expanding its market presence in the country.

Lupin Limited proudly announces their first entry into the Chinese pharmaceutical market with the approval of oseltamivir oral suspension, enhancing pediatric care access.

Lupin Limited has gained approval for its Oseltamivir phosphate suspension in China, marking a significant step in its global expansion strategy, particularly for pediatric care.

Lupin Limited proudly announces the approval of Oseltamivir Phosphate in China, marking a significant entry into the Chinese pharmaceutical market.

Lupin Limited proudly announces the approval of an oral suspension of oseltamivir phosphate in China, marking a key milestone in its global expansion efforts.

Lupin Limited secures approval for Oseltamivir Phosphate Oral Suspension in China, marking a strategic entry into a significant market alongside Yabao Pharmaceuticals.